Earnings summaries and quarterly performance for Option Care Health.
Executive leadership at Option Care Health.
John C. Rademacher
Detailed
President and Chief Executive Officer
CEO
Christopher L. Grashoff
Detailed
Chief Growth Officer
Collin G. Smyser
Detailed
General Counsel and Corporate Secretary
Femi Adewunmi, M.D.
Detailed
Chief Medical Officer
Luke Whitworth
Detailed
Chief Operating Officer
Meenal Sethna
Detailed
Chief Financial Officer
Michael Bavaro
Detailed
Chief Human Resources Officer
Board of directors at Option Care Health.
Barbara W. Bodem
Detailed
Director
David W. Golding
Detailed
Director
Elizabeth D. Bierbower
Detailed
Director
Elizabeth Q. Betten
Detailed
Director
Eric K. Brandt
Detailed
Director
Harry M. Jansen Kraemer, Jr.
Detailed
Independent Board Chair
Natasha Deckmann, M.D.
Detailed
Director
Norman L. Wright
Detailed
Director
R. Carter Pate
Detailed
Director
Timothy P. Sullivan
Detailed
Director
Research analysts who have asked questions during Option Care Health earnings calls.
Constantine Davides
Citizens JMP
4 questions for OPCH
Also covers: ADUS, AMN, CCRN +9 more
Joanna Gajuk
Bank of America
4 questions for OPCH
Also covers: ACHC, ADUS, AGL +21 more
Pito Chickering
Deutsche Bank
4 questions for OPCH
Also covers: ACHC, AHCO, AVAH +18 more
Brian Tanquilut
Jefferies
3 questions for OPCH
Also covers: ACHC, ADUS, AHCO +29 more
David Macdonald
Truist Securities
3 questions for OPCH
Also covers: AVAH, ENSG, GRDN +3 more
Lisa Gill
JPMorgan Chase & Co.
3 questions for OPCH
Also covers: AGL, CAH, CI +13 more
Matthew Larew
William Blair & Company
3 questions for OPCH
Also covers: AMED, ATR, DNA +10 more
A.J. Rice
UBS Group AG
2 questions for OPCH
Also covers: ACHC, AMED, AMN +20 more
Sarah Conrad
Goldman Sachs
2 questions for OPCH
Jack Slevin
Jefferies Financial Group Inc.
1 question for OPCH
Also covers: AGL, AMN, ASTH +8 more
Jamie Perse
The Goldman Sachs Group, Inc.
1 question for OPCH
Also covers: BTSG, CON, DOCS +8 more
Recent press releases and 8-K filings for OPCH.
Option Care Health Reports Strong Q3 2025 Performance and Positive Outlook
OPCH
Guidance Update
Debt Issuance
M&A
- Option Care Health reported strong Q3 2025 results with 12% top-line growth, 3.4% adjusted EBITDA growth, and 9.8% adjusted diluted EPS growth, leading to an increase in adjusted EBITDA guidance by $15 million and adjusted EPS projection by $0.06.
- The company maintains a strong financial position with 1.9 times leverage and expects to generate over $320 million of cash flow from operations in 2025, having recently refinanced its first lien debt to extend maturity to 2032 and add $50 million to its capital profile.
- Option Care Health anticipates a $60 million-$70 million headwind for 2025, at the higher end of the range, primarily due to changes in Stelara discounts and patient migration to biosimilars, which resulted in a 380 basis point headwind to chronic revenue in Q3.
- The company is focused on strategic growth through tuck-in M&A, leveraging its existing infrastructure for an advanced practitioner model, and has seen infusion suite utilization for nursing visits increase from 16% in 2021 to 34% in 2024.
5 days ago
Option Care Health Reports Strong Q3 2024 Results and Updates 2025 Guidance
OPCH
Guidance Update
Revenue Acceleration/Inflection
M&A
- Option Care Health reported strong Q3 2024 results, including 12% top-line growth, 3.4% adjusted EBITDA growth, and 9.8% adjusted diluted EPS growth. The company also raised its adjusted EBITDA guidance by $15 million and adjusted EPS projection by an additional $0.06 for the year.
- The company maintains a strong financial position with 1.9x leverage after refinancing its first lien debt in Q3 2024, extending the principal to 2032, and expects to generate over $320 million of cash flow from operations.
- Option Care Health anticipates a $60 million-$70 million headwind in 2025 due to the Stelara biosimilar impact, now projected at the higher end of this range, which caused a 380 basis point headwind to chronic revenue in Q3.
- The company's M&A strategy is focused on disciplined tuck-ins and adjacencies to enhance market presence and clinical capabilities, rather than pursuing transformative deals.
5 days ago
Option Care Health Reports Strong Q3 Performance and Raises Full-Year 2025 Guidance
OPCH
Earnings
Guidance Update
Share Buyback
- Option Care Health reported strong Q3 performance, with Net Revenue of $1,435.0 million (+12.2%), Adjusted EBITDA of $119.5 million (+3.4%), and Adjusted diluted EPS of $0.45 (+9.8%) compared to the prior year.
- The company raised its full-year 2025 guidance as of October 30, 2025, now expecting Net Revenue between $5.60 billion and $5.65 billion, Adjusted diluted EPS from $1.68 to $1.72, and Adjusted EBITDA from $468 million to $473 million. They also anticipate generating over $320 million in Cash Flow from Operations for 2025.
- Option Care Health demonstrated strong capital allocation in Q3, repurchasing $62 million of stock and refinancing its term loan, which reduced borrowing costs, extended maturity, and added $50 million in liquidity.
- The company maintains a robust balance sheet with $706 million in liquidity as of Q3'25 and a Net Debt Leverage Ratio of 1.9x. From 2021 to Q3'25, it generated $1.4 billion in operating cash flow and deployed $1.2 billion across Capex, acquisitions, and share repurchases.
5 days ago
Option Care Health Reports Strong Q3 2025 Results and Updates Guidance
OPCH
Guidance Update
Revenue Acceleration/Inflection
M&A
- Option Care Health reported strong Q3 2025 financial results, including 12% top-line growth, 3.4% adjusted EBITDA growth, and 9.8% adjusted diluted EPS growth.
- The company raised its adjusted EBITDA guidance by $15 million and its adjusted EPS projection by an additional $0.06 for the year.
- Option Care Health expects a $60 million-$70 million headwind for 2025 due to the impact of Stelara biosimilars, with the impact currently at the higher end of this range.
- The company maintains a strong capital structure with 1.9 times leverage and expects to generate over $320 million of cash flow from operations.
- M&A strategy is focused on tuck-in acquisitions and adjacencies, not transformative deals, leveraging its existing infrastructure and market presence.
5 days ago
Option Care Health Discusses 2025 Stelara Headwinds and Midterm Growth Outlook
OPCH
Guidance Update
Share Buyback
New Projects/Investments
- Option Care Health anticipates a $60 million to $70 million headwind in 2025, likely at the higher end of this range, due to changes in the Stelara product's discount profile, driven by biosimilar introductions and IRA negotiations.
- Despite these headwinds, the company expects to achieve growth in revenue, adjusted EBITDA, and adjusted EPS in 2026.
- Over the midterm, Option Care Health projects high single-digit top-line growth and low double-digit bottom-line growth (adjusted EBITDA), with adjusted EPS growing even higher.
- The company's capital deployment strategy includes investing in the business, pursuing disciplined M&A, and executing share buybacks, having repurchased over $212 million in shares through Q2 2025.
Nov 19, 2025, 3:30 PM
Option Care Health Discusses Stelara Headwinds and Reiterates 2026 Growth Expectations
OPCH
Guidance Update
Share Buyback
New Projects/Investments
- Option Care Health (OPCH) anticipates a $60 million to $70 million headwind in 2025 due to reduced Stelara discounts, with the impact patterning towards the high end of this range. The company is still evaluating the full impact for 2026, considering biosimilar transitions and ongoing negotiations with manufacturers.
- Despite these challenges, OPCH expects to achieve growth in revenue, adjusted EBITDA, and adjusted EPS in 2026.
- The company maintains a mid-term goal of high single-digit top-line growth and low double-digit bottom-line (EBITDA) growth, although 2026 may not reach this level.
- OPCH has been actively deploying capital, including over $212 million in share buybacks through Q2 2025.
- The company is leveraging its position as the largest independent provider of home and alternate site infusion therapy in the U.S. and capitalizing on competitive dynamics where other providers are exiting markets.
Nov 19, 2025, 3:30 PM
Option Care Health Discusses 2025 Performance, Growth Strategy, and Stelara Headwinds
OPCH
Guidance Update
Revenue Acceleration/Inflection
New Projects/Investments
- Option Care Health reported a strong year, raising its adjusted EBITDA guidance by $15 million and adjusted EPS target by 6 cents for 2025, and maintains a long-term growth algorithm of high single-digit revenue growth, low double-digit EBITDA growth, and EPS growth higher than EBITDA.
- The company is navigating a $60 million-$70 million gross profit headwind in 2025 related to the Stelara drug and biosimilar competition, but expects to grow through this in 2026.
- Growth opportunities include new therapies, pharma partnerships, an advanced practitioner model in 24 of its 170 facilities, and strategic tuck-in M&A, supported by strong cash generation for capital allocation and opportunistic share buybacks.
Nov 11, 2025, 8:30 PM
Option Care Health Updates 2025 Guidance and Discusses Long-Term Growth
OPCH
Guidance Update
New Projects/Investments
Revenue Acceleration/Inflection
- Option Care Health has raised its adjusted EBITDA guidance by $15 million and adjusted EPS target by $0.06 for the full year 2025.
- Since 2020, the company has demonstrated strong financial performance, with revenue growing by a 13% CAGR, EBITDA by a 19% CAGR, and operating cash flow by a 26% CAGR.
- Despite experiencing headwinds from the STELARA drug in 2025 and anticipating continued headwinds in 2026 due to biosimilars and next-generation drugs, the company projects growth in revenue, EBITDA, and EPS for 2025 and expects to grow in 2026.
- Management expresses confidence in its long-term growth algorithm, targeting high single-digit revenue growth, low double-digit EBITDA growth, and higher EPS growth for 2026 and beyond.
- The company is making investments in SG&A, including an AI partnership with Palantir, to streamline processes and is noted as a strong cash generator with a cash conversion cycle in single days.
Nov 11, 2025, 8:30 PM
Option Care Health Updates 2025 Guidance and Discusses Growth Strategy
OPCH
Guidance Update
New Projects/Investments
Share Buyback
- Option Care Health (OPCH) has raised its adjusted EBITDA guidance by $15 million and adjusted EPS target by 6 cents for 2025, expressing confidence in its full-year guidance and anticipating growth in 2026 despite headwinds.
- The company is managing a $60 million-$70 million gross profit headwind in 2025 from the Stelara drug due to discount rate changes and biosimilar entry, yet its chronic sales still achieved double-digit growth.
- OPCH reaffirms its long-term growth algorithm targeting high single-digit revenue growth, low double-digit EBITDA growth, and higher EPS growth.
- Strategic initiatives include maximizing capacity in its 170 infusion suites, leveraging its NAVEN nursing network, and investing in AI to streamline operations and enhance cash flow.
- Capital deployment focuses on tuck-in M&A and opportunistic share buybacks, supported by the company's strong cash generation.
Nov 11, 2025, 8:30 PM
Option Care Health Reports Strong Q3 2025 Results, Raises Full-Year Guidance, and Appoints New CFO
OPCH
Earnings
CFO Change
Guidance Update
- Option Care Health announced that Meenal Sethna joined as Chief Financial Officer on October 1st, replacing Mike Shapiro.
- For Q3 2025, the company reported 12% revenue growth, with acute therapy growth in the mid-teens and chronic therapies growing in the low double digits. Adjusted EBITDA reached $119.5 million, a 3.5% increase, and adjusted earnings per share was $0.45, up 9.8%.
- The company raised the midpoints of its full-year 2025 guidance, now expecting revenue between $5.6 billion and $5.65 billion, adjusted EBITDA between $468 million and $473 million, and adjusted EPS between $1.68 and $1.72.
- The chronic portfolio's growth was negatively impacted by 380 basis points in Q3 due to the adoption of Stelara biosimilars, with the full-year 2025 impact expected to be at the higher end of the $65 million-$70 million range.
- Option Care Health's capital allocation strategy prioritizes internal investments for profitable growth, followed by strategic tuck-in acquisitions, and then share repurchases, having bought back over $62 million in shares during the quarter.
Oct 30, 2025, 12:30 PM
Quarterly earnings call transcripts for Option Care Health.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more